Portfolio Companies

Medicus Oncology, a wholly owned subsidiary of Medicus Pharma Ltd. (NASDAQ:MDCX), is a clinical-stage oncology company building a portfolio of differentiated, high-potential oncology programs. Our foundational asset is CD228V, an investigational antibody drug conjugate molecule utilizing Pfizer established vedotin linker payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types such as melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer.